Summary: Evidence from electronic medical record (EMR) and pharmacy claims data for Medicare beneficiaries, suggests that for patients initiating treatment with anti-epileptic drugs (AEDs) (specifically, lonazepam, gabapentin, oxcarbazepine, phenytoin, or zonisamide) use of a generic AED is associated with a lower risk of a seizure-related hospitalization, and a longer time to the first gap in medication use, compared to treatment with a brand-name AED.
Strength of Recommendation = C